The E3 Ligase TRAF6 Regulates Akt Ubiquitination
Thus, some of the same receptors that detect noxious compounds on the tongue to protect animals from ingesting harmful material may also defend human airways. The receptors are positioned on cilia, a location optimal for sampling air and material entering the lung. Moreover, the bitter compound denatonium stimulated ciliary activity, which should hasten elimination of noxious and harmful substances. Substances that activate T2Rs might enter airways through inhalation or aspiration or be generated within the lung by infection. We speculate that this signaling system might also play a role in airway disease. For example, in cystic fibrosis, lungs are commonly infected with Pseudomonas aeruginosa. This bacterium produces quorum-sensing molecules that are lactones, which activate some bitter taste receptors (23, 24) . Airway T2Rs might also be activated by cigarette smoke, which contains the bitter-tasting compound nicotine (25) . In addition, airway cilia are lost in some viral infections and with cigarette smoking (26) , which would disrupt this defensive system.
Previous work suggested general roles for the two types of vertebrate cilia-primary cilia are sensory and motile cilia are mechanical. Studies of primary nodal cilia in mouse embryos indicated that the distinction is not absolute; those cilia can exhibit a rotational movement different from the planar beating typical of motile cilia (4, 5) . In addition, proteomic studies of Chlamydomonas flagella identified numerous proteins involved in signal transduction (27) . Our present data indicate that classical motile cilia also have a sensory function.
T2Rs on taste receptor cells, which are not known to have primary cilia, detect bitter ligands and transmit that information to nerves to elicit a response (15, 20) . In cells outside the tongue where a-gustducin and T2Rs have been identified-nasal and laryngeal solitary chemosensory cells and intestinal tract enteroendocrine cells-signals are transmitted to the associated nerve networks (28-30). In contrast, in airway epithelia, T2Rs enable cell-autonomous detection of a signal followed by a response in the same cell to eliminate harmful substances. 27 S1A ). Ubiquitination occurred through K63 but not through K48 (Fig. 1A) . Akt ubiquitination could be modified by K11-linked ubiquitin but not through K6 and K48 linkages ( fig. S1B ).
We screened a panel of E3 ubiquitin ligases for Akt ubiquitination. Although Mdm2 E3 ligase interacts with Akt (4-6), it failed to promote Akt ubiquitination ( fig. S2A ), as did c-IAP1, c-IAP2, Cbl-b, Itch, Smurf2, and Fbw7 ( fig.  S2A ). Overexpression of c-IAP1 and c-IAP2 reduced Akt ubiquitination ( fig. S2, A and B) . Because Akt underwent K63 ubiquitination, we focused on TRAF6 and HectH9, two E3 ubiquitin ligases that catalyze K63 ubiquitination and function in Toll-like receptor (TLR) or interleukin-1 (IL-1) signaling and oncogenic activation of Myc, respectively (7) (8) (9) . TRAF6 promoted Akt ubiquitination, whereas HectH9 did not (Fig. 1B) .
Activity of Akt was not required for TRAF6-mediated ubiquitination ( fig. S2C ). However, TRAF6 E3 ligase activity was required. The TRAF6 C 70 →A 70 [C70A (3)] mutant, which loses E3 ligase activity (9), had compromised activity (Fig. 1C) , which was not due to a defect in Akt interaction ( fig. S3A ). Although TRAF6 induced Akt ubiquitination, it did not decrease the abundance of Akt (Fig. 1, B and C), suggesting it does not mediate K48 ubiquitination. Indeed, TRAF6 promoted K63 ubiquitination of Akt but not K48 ubiquitination (Fig. 1D) . TRAF6, but not TRAF6 C70A, induced Akt ubiquitination in vitro (Fig. 1E and  fig. S2D ). These results suggest that TRAF6 is an E3 ubiquitin ligase for Akt.
Coimmunoprecipitation experiments revealed that Akt interacted with overexpressed TRAF6 and with TRAF6 C70A (fig. S3A ). We detected interaction between endogenous Akt and TRAF6 in cells stimulated with insulin-like growth factor-1 (IGF-1) or IL-1b ( fig. S3B ), both of which activate Akt signaling. Glutathione-Stransferase (GST)-tagged TRAF6 interacted with Akt directly in vitro ( fig. S3C ). Ubiquitination of the Akt1 and Akt2 isoforms, but not that of Akt3, was induced by TRAF6 ( fig.  S4A ). Coimmunoprecipitation assay revealed that TRAF6 interacted with all Akt isoforms ( fig. S4B) .
Overexpression of TRAF6, but not that of TRAF6 C70A, enhanced phosphorylation of Akt at T308 (3) but not at S473, and this enhancement was accompanied by increased Akt activity toward glycogen synthase kinase 3b (GSK3b) (Fig. 1F) (10, 11) . A control E3 ligase, HectH9, failed to regulate phosphorylation of Akt ( fig. S5) . Overexpression of c-IAP1 and c-IAP2, which slightly inhibited ubiquitination of Akt, reduced phosphorylation of Akt on T308 ( fig. S2B) -/-mice (n = 4) injected with IGF-1 at various time points were subjected to an in vitro Akt kinase assay and IB analysis.
28 AUGUST 2009 VOL 325 SCIENCE www.sciencemag.org cells stimulated with IGF-1 or IL-1b, whereas restoration of TRAF6 C70A did not (Fig. 2C  and fig. S6E ). Thus, TRAF6 is critical for Akt phosphorylation and activation through induction of Akt ubiquitination.
Because Akt influences cell survival and apoptosis (10, 11), we tested whether Traf6 deficiency sensitized cells to apoptosis after serum withdrawal. Apoptosis in Traf6 -/-MEFs was higher than in Traf6 +/+ MEFs in the presence and absence of serum (Fig. 2D and fig. S9 ). The active, cleaved form of caspase 3, a mediator of apoptosis, was more abundant in Traf6 -/-
MEFs than in Traf6
+/+ MEFs ( fig. S10A ). Restoration of TRAF6, but not TRAF6 C70A, rescued Traf6 −/− MEFs from apoptosis (Fig. 2E) . A constitutively active form of Akt partially rescued cells from apoptosis (Fig. 2E) . Thus, other signaling pathways may be also involved. Because apoptosis inducers such as DNA damage agents induce phosphorylation and activation of Akt (12, 13), we tested whether TRAF6 was also involved. Doxorubicin (Dox)-and cisplatin (Cis)-induced phosphorylation of Akt T308 in wild-type MEFs was impaired in Traf6 −/− MEFs ( fig. S10B ). The impairment of Akt phosphorylation was correlated with increased caspase 3 activation in Traf6 −/− MEFs ( fig. S10C ).
TRAF6 is expressed in most mouse tissues (14, 15) . We compared Akt activity in skeletal muscle and heart tissues from wild-type and Traf6 −/− mice. Steady-state Akt activity in heart muscle, but not skeletal muscle, was lower in Traf6 −/− mice than in wild-type mice ( fig. S11 ). Akt activation in animals injected with IGF-1 was impaired in both forms of muscles in Traf6 −/− mice (Fig. 2F) . These results suggest that TRAF6 plays a critical role in Akt activation in vivo.
Because the pleckstrin homology (PH) domain of Akt is critical for phosphatidylinositol (3,4,5)-trisphosphate (PIP3) lipid binding and protein-protein interaction (16, 17) , we analyzed whether the PH domain of Akt influenced TRAF6-mediated ubiquitination of Akt. TRAF6 failed to promote ubiquitination of the Akt mutant devoid of the PH domain (Fig. 3A) . Of the six lysine residues within the PH domain of Akt, mutation on either K8 or K14 to arginine (R) most substantially reduced Akt ubiquitination and Akt phosphorylation at T308 and S473 (Fig. 3B) . The K8 and K14 residues are well conserved from Drosophila to humans ( fig. S12) , suggesting that the ubiquitination of Akt may be evolutionarily conserved.
Akt K8R bound effectively to isolated PIP3, but Akt K14R did not (Fig. 3C) . The K14 residue lies within the PIP3 lipid-binding pocket (18) (19) (20) . Overexpression of TRAF6 did not enhance the binding of Akt to PIP3 (Fig. 3C) . Thus, Akt ubiquitination by TRAF6 appears not to influence PIP3 lipid binding, and the defect in phosphorylation of Akt K8R is not due to its impairment in PIP3 binding.
A mutation in the PH domain [E 17 →K 17 , E17K (3)] of Akt has been identified in human cancer patients, including those with breast cancer (19) . This cancer-associated Akt mutant exhibited constitutive Akt phosphorylation at T308 but not at S473 and had greater oncogenic potential. Basal ubiquitination of the E17K mutant was much higher than that of wild-type Akt (Fig.  3D) . Overexpression of TRAF6 still increased ubiquitination of this mutant but to a lesser extent than wild-type Akt (Fig. 3D) . The E17K mutant displayed higher Akt phosphorylation at T308 but not at S473 (19) , and this was not increased by TRAF6 overexpression (Fig. 3D) . Ubiquitination of a K8R/E17K Akt mutant in vivo was reduced and correlated with a reduction in phosphorylation of Akt T308 (Fig. 3E) . Thus, increased Akt ubiquitination apparently contributes to the hyperactivation of Akt observed in the Akt E17K mutant.
Because K63 ubiquitination regulates protein trafficking, we tested whether TRAF6 influenced membrane recruitment of Akt. Overexpression of TRAF6 increased Akt membrane localization, which correlated with an increase in phosphorylation and ubiquitination of Akt (Fig. 3A) . IGF-1-induced Akt membrane localization and T308 phosphorylation in wild-type MEFs was abolished in Traf6 -/-MEFs (Fig. 4B) . 
We also compared the membrane recruitment of wild-type Akt and Akt mutants (K8R and K14R), which are defective in Akt ubiquitination. Membrane recruitment of Akt K8R and K14R upon IGF-1 treatment was reduced (Fig.  4C and fig. S13 ). The Akt E17K mutant localized to the membrane, even without IGF-1 stimulation, although IGF-1 stimulation further increased membrane recruitment (Fig. 4C and fig. S13 ).
The Akt K8R/E17K mutant showed impaired association with the membrane (Fig. 4C and fig.  S13 ). This suggests that Akt ubiquitination contributes to membrane recruitment and phosphorylation of Akt.
Because deregulated Akt can contribute to cancer development (21, 22) , we depleted TRAF6 in PC-3 prostate cancer cells by using short hairpin RNAs (shRNAs). Depletion of TRAF6 reduced Akt phosphorylation at T308 and S473 (Fig. 4D) . In cells treated with IGF-1, Akt phosphorylation in TRAF6 knockdown cells was impaired (Fig. 4E) . In xenograft tumor models, the two stable TRAF6 knockdown cells had lower tumorigenic potential than control cells (Fig. 4F and fig. S14 ). Thus, TRAF6 appears to influence tumorigenesis in this model.
TRAF6 has an important role in TLR signaling and the innate immune response. Our results expand its known function to include the survival and oncogenic signaling pathways ( fig. S15) . We suggest that TRAF6 may be a previously uncharacterized oncogene that may serve as an important therapeutic target for human cancers.
Supporting Online Material (1, 2) . MEFs, NIH3T3, COS-1, and 293T cells were cultured in DMEM containing 10% FBS. pcDNA6-HA-Akt1 K8R, pcDNA6-HA-Akt1 K14R, pcDNA6-HA-Akt1 K20R, pcDNA6-HAAkt1 K30R, pcDNA6-HA-Akt1 K39R, pcDNA6-HA-Akt1 K64R, pcDNA6-HA-Akt1 E17K, and pcDNA6-HA-Akt1 K8R/E17K constructs were generated using a site-directed mutagenesis kit (Stratagene) according to the manufacturer's standard procedures with pcDNA6-HA-Akt1 as the template. Flag-TRAF6, Flag-TRAF6 C70A, pGEX-4X1-TRAF6, and pGEX-4X1-TRAF6 C70A constructs have been described previously (3) . Akt KD (Akt K179A) and Mdm2 have been described previously (4) . (His) GST pulldown assays. For in vitro TRAF6 and Akt1 interaction, GST, GST-TRAF6, and GST-TRAF6 C70A proteins purified from the bacterial lysates of BL21 competent cells transformed with pGEX-4X1, pGEX-4X1-TRAF6, and pGEX-4X1-TRAF6 C70A using glutathione-agarose beads according to the manufacturer's standard procedures. The GST, GST-TRAF6, and GST-TRAF6 C70A proteins bound to glutathione Sepharose beads (Amersham Biosciences) were then incubated with the in vitro translated [35S]-Akt1 for 4 h at 4°C in the interaction buffer [20 mM HEPES (pH 7.9), 150 mM KCl, 5 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.1% (v/v) NP-40, 0.1% (w/v) BSA, 1 mM PMSF, and 10% glycerol], washed with NETN buffer [20 mM Tris (pH 8.0), 100 mM NaCl, 6 mM MgCl2, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM DTT, 8% glycerol, and 1 mM PMSF] 4 times, and subjected to 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by autoradiography.
Ubiquitination assay. In vivo ubiquitination assays were performed as described elsewhere (5). In brief, 293T cells were transfected with the indicated plasmids for 48 h and lysed by denatured buffer (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM imidazole), followed by nickel bead purification and Immunoblot analysis. In vitro ubiquitination assays using GST-TRAF6 and GST-AKT-Flag were performed as described elsewhere (3). Purified GST-TRAF6 and GST-AKT-Flag were incubated for 3 h at 37°C in 20 µl of reaction buffer [20 mM Hepes (pH 7.4), 10 mM MgCl2, 1 mM DTT, 59 µM ubiquitin, 50 nM E1, 850 nM of Ubc13/UeV1a, 1 mM ATP, 30 µM creatine phosphate, and 1 U of creatine kinase]. After incubation, the beads were washed five times in Buffer A [20 mM Tris (pH 7.4), 250 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate, 2 mM EDTA, and 1% Triton X-100] and two times in low-salt buffer [20 mM Tris [pH 7.4], 25 mM NaCl, and 1 mM DTT]. Beads were then resuspended in 1% SDS (in water) and boiled for 10 min. Dissociated proteins were diluted with 2×600 µl Buffer A, and the supernatant fluid was precleared with Protein A/G beads for 1 h, and immunoprecipitated overnight with 1 µg anti-Flag antibody, after which Protein A/G beads were added for an additional 1 h. Beads were washed 4 times with Buffer A and 2 times with low-salt buffer. Proteins were eluted in SDS-sample buffer, subjected to SDSPAGE, transferred to nitrocelluose membrane, and immunoblotted with anti-ubiquitin. PIP3 phospholipid binding. 293T cells transfected with WT HA-Akt and various HA-Akt mutants for 48 h were lysed by E1A buffer, and the cell lysates were incubated with control beads or PIP3 beads (Enchelon) overnight. The beads were washed four times with E1A buffer and subjected to Immunoblot analysis.
Membrane fractionation. MEFs were serum-starved for 48 h in DMEM containing 0.1% FBS, and cytosolic and membrane fractions were prepared using the ProteoExtract kit (Calbiochem) according to the manufacturers' standard procedures.
Cell apoptosis assay. WT and Traf6
-/-MEFs were serum-starved (0.1% FBS) or cultured in 10% FBS for 2 days, and cells were collected and labeled with Annexin-V-FITC, followed by flow cytometry analysis.
Viral infection and in vivo tumorigenesis assay.
For retroviral infection, retroviral plasmid PMX, PMX-TRAF6, and PMX-TRAF6 C70A were transfected into Phoenix packing cells for 2 days, and the virus-containing medium was harvested and used to infect primary WT and Traf6 -/-MEFs. For lentiviral short hairpin RNA (shRNA) infection, 293T cells were cotransfected TRAF6 or GFP control shRNA with packing plasmids (deltaVPR8.9) and envelope plasmid (VSV-G) using Lipofectamine 2000 reagent according to the manufacturer's instructions. TRAF6-lentivivral shRNA-1 (5'-GCCACGGGAAATATGTAATATCT-3'), TRAF6-lentivivral shRNA-2 (5' CGAAGAGATAATGGATGCCAAC-3'), control shRNA (5'-GCAAGCTGACCCTGAAGTTC-3') were transfected with packing plasmids into 293T cells for 2 days, and virus particles containing TRAF6 or control shRNAs were used to infect PC-3 cells. All the infected cells were cultured in medium containing 2 µg/ml puromycin for 4 days. For in vivo tumorigenesis assays, PC-3 stable cells ( 2×10 6 ) mixed with matrigel (1:1) were subcutaneously injected into the left flank of 6-week-old athymic nude mice. Tumor size was measured weekly using a caliper, and tumor volume was determined by using the standard formula: L×W2×0.52, where L is the longest diameter and W is the shortest diameter.
Assessing Akt activity in vivo in mice tissues. Heart and skeletal tissues isolated from 2-week-old WT and Traf6 -/-mice (n=5) were lysed in RIPA buffer, and lysates were used to determine Akt activity using the Akt kinase assay kit (Cell Signaling) according to the manufacturer's standard procedures. For IGF-1 injection, 2 week-old WT and Traf6 -/-mice (n=4) were starved for 6 h and intraperitoneally injected with IGF-1 (0.5 mg/kg) for various times. Skeletal and heart muscles were then isolated for the in vitro Akt kinase assay. ]-Akt, washed, and subjected to SDS-PAGE, followed by autoradiography. -1. (A, B) COS-1 and PC-3 cells were serum-starved for 1 day and treated with or without 100 ng/ml of IGF-1; WCE were collected for immunoprecipitation with TRAF6, followed by immunoblot analysis with anti-ubiquitn antibody (A) or anti-IGF-1Rβ antibody (B). -/-MEFs were cultured in 10% FBS or serumstarved for 2 days, and cell apoptosis was determined by Annexin-V staining, followed by flow cytometry analysis. 
